NCT03165864View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

September 25, 2018

Study Completion Date

September 25, 2018

Conditions
Thalassemia
Interventions
DRUG

IONIS TMPRSS6-Lrx

Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously

OTHER

Placebo

Saline .9%

Trial Locations (1)

VIC 3004

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY